GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Navidea Biopharmaceuticals Inc (OTCPK:NAVB) » Definitions » Cyclically Adjusted Book per Share

Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Cyclically Adjusted Book per Share : $-2.02 (As of Sep. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Navidea Biopharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Navidea Biopharmaceuticals's adjusted book value per share for the three months ended in Sep. 2023 was $-0.033. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-2.02 for the trailing ten years ended in Sep. 2023.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -18.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -1.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Navidea Biopharmaceuticals was 15.90% per year. The lowest was -104.90% per year. And the median was -20.10% per year.

As of today (2024-05-02), Navidea Biopharmaceuticals's current stock price is $0.035. Navidea Biopharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $-2.02. Navidea Biopharmaceuticals's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Navidea Biopharmaceuticals was 212.86. The lowest was 58.40. And the median was 99.71.


Navidea Biopharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Navidea Biopharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navidea Biopharmaceuticals Cyclically Adjusted Book per Share Chart

Navidea Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.67 -1.17 -1.14 -1.63 -1.93

Navidea Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.93 -1.93 -1.95 -1.96 -2.02

Competitive Comparison of Navidea Biopharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Navidea Biopharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Navidea Biopharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Navidea Biopharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Navidea Biopharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Navidea Biopharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Navidea Biopharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book= Book Value per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.033/129.8595*129.8595
=-0.033

Current CPI (Sep. 2023) = 129.8595.

Navidea Biopharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201312 -0.590 98.326 -0.779
201403 -1.950 99.695 -2.540
201406 -3.165 100.560 -4.087
201409 -4.148 100.428 -5.364
201412 -3.968 99.070 -5.201
201503 -4.760 99.621 -6.205
201506 -5.983 100.684 -7.717
201509 -6.939 100.392 -8.976
201512 -6.978 99.792 -9.080
201603 -7.412 100.470 -9.580
201606 -8.272 101.688 -10.564
201609 -8.250 101.861 -10.518
201612 -8.749 101.863 -11.154
201703 2.786 102.862 3.517
201706 2.056 103.349 2.583
201709 1.892 104.136 2.359
201712 1.403 104.011 1.752
201803 0.525 105.290 0.648
201806 0.259 106.317 0.316
201809 0.148 106.507 0.180
201812 0.174 105.998 0.213
201903 -0.057 107.251 -0.069
201906 0.125 108.070 0.150
201909 -0.042 108.329 -0.050
201912 -0.084 108.420 -0.101
202003 -0.086 108.902 -0.103
202006 -0.096 108.767 -0.115
202009 0.006 109.815 0.007
202012 0.048 109.897 0.057
202103 0.149 111.754 0.173
202106 0.189 114.631 0.214
202109 0.113 115.734 0.127
202112 -0.004 117.630 -0.004
202203 -0.079 121.301 -0.085
202206 -0.149 125.017 -0.155
202209 -0.154 125.227 -0.160
202212 -0.258 125.222 -0.268
202303 -0.300 127.348 -0.306
202306 -0.011 128.729 -0.011
202309 -0.033 129.860 -0.033

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Navidea Biopharmaceuticals  (OTCPK:NAVB) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Navidea Biopharmaceuticals was 212.86. The lowest was 58.40. And the median was 99.71.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Navidea Biopharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Navidea Biopharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
Executives
Craig Dais officer: Chief Financial Officer 4995 BRADENTON AVENUE, SUITE 240, DUBLILN OH 43017
Dana J Moss director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jill Stefanelli director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Josh M Wilson director 4795 BRADENTON AVE, STE 240, DUBLIN OH 43017
Scott John K Jr. director, 10 percent owner 30 BLUE HERON DR., GREENWOOD VILLAGE CO 80121
Agnieszka Winkler director C/O INTER-TEL, INCORPORATED, 1615 SOUTH 52ND STREET, TEMPE AZ 85281
Thomas F Farb director C/O SUMMIT PARTNERS, 222 BERKELEY ST 18TH FL, BOSTON MA 02116
Michel Mikhail officer: Chief Regulatory Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Malcolm G Witter director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Alexander L Cappello director C/O THE CHEESECAKE FACTORY INC, 26901 MALIBU HILLS ROAD, CALABASAS HILLS CA 91301
Amit Bhalla director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Joel H. Kaufman officer: Chief Business Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jed Latkin officer: Interim COO 152 W. 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Sarah Kathryn Rouan director 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017
Claudine Bruck director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552